当前位置:首页 > 报告详情

Olympus-44th_J.P._Morgan_Healthcare_Conference.pdf

上传人: 明**** 编号:1069844 2026-01-17 14页 1.08MB

1、INTERNAL USE ONLYOlympus Corporate StrategyWhere Purpose Meets PerformanceJP Morgan ConferenceJanuary 13,20262 2Disclaimer This material contains forward-looking statements that reflect managements current views,plans,and expectations based on information available at the time of preparation.These f

2、orward-looking statements are not guarantees of future performance and involve known and unknown risks,uncertainties,future business decisions,and other internal and external factors that may cause the Companys actual results,performance,achievements,or financial position to be materially different

3、from any future results expressed or implied by these forward-looking statements.Additionally,this information is subject to change without notice.Accordingly,other information should be used in addition to this material when making investment decisions.This material is not intended for promotional

4、or medical advice use.Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.It is provided to give examples of technology development by Olympus and no guarantees are made about the future sale of such

5、products.Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.3 3Global Trends Show Increasing Demand for Endoscopy Procedures,Underpinned by Macroeconomic Factors and the Need for Better Care1.Market value growth base on AcuityMD,Ministries of Health,

6、IQVIA FlexView MedTech,Olympus China primary market research.2.Based on Olympus market insights derived from IQVIA FlexView MedTech.3.Assumes global per capita utilization matches US/EU/Japan/China levelsGlobal demand drives 5%annual growth of Global demand drives 5%annual growth of endoscopyendosco

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **市场增长**:全球内镜手术需求年增5%,受老龄化、癌症发病率上升及医疗可及性提升驱动,2025年全球手术量达12亿例。 2. **战略支柱**: - **创新驱动**:通过OLYSENSE AI、机器人(如Swan合作)及内镜扩张(如EVIS X1、一次性器械)引领增长,目标FY29营收增5%。 - **简化运营**:裁员2000人,节省240亿日元,优化供应链及SG&A。 3. **财务目标**:FY27-29营业利润率23-4-5%,EPS年增超10%,资本优先投资增长及股东回报(分红+回购)。 4. **区域布局**:中国本地化生产强化复苏,新兴市场双位数增长,应对监管及关税压力。
**增长动力何在?** **AI如何革新内镜?** **中国市场机遇?**
客服
商务合作
小程序
服务号
折叠